Latest News
Investment bank GCA Savvian Corporation and financial advisory group Altium are to merge to form an independent international investment bank focused on growth companies with an extensive global network, cross-border capability and track record of industry-shaping transactions.
The combined company will operate under the names GCA Altium in Europe and GCA in the United States and Asia.
Upon the completion of the transaction, GCA will be a leading global pure play advisory business with a focus on growth companies and the 7th largest listed M&A advisory firm in the world, with more than USD185 million in advisory revenues, approximately 370 staff, 300
Infrastructure investments have held up over the past five years but political and regulatory risk dominates investors’ lists of concerns according to the latest infrastructure investors survey from Deloitte, the business advisory firm.
Deloitte surveyed 25 European infrastructure investors, including infrastructure funds and direct lenders, together holding over GBP200 billion in assets and ‘dry powder’, for its 2016 survey, the fourth in its series.
92 per cent of respondents say their infrastructure investments have proved resilient over the last five years, with 8 per cent saying performance has been mixed
Investors have cut their target internal rates of
Apposite Capital, a private equity firm specialising in healthcare, has made a new investment in Medical Imaging Partnership (MIP), a UK-based provider of medical diagnostic imaging services.
Apposite will make available up to GBP12m to support the geographical roll-out of MIP services across the UK, grow the management team and employee base, and continue investing in high quality radiology services for patients and clinicians.
Created in 2010, MIP has built an excellent reputation and has a well-established long standing customer base within the NHS and the independent sector. MIP offers fully managed clinical services whereby it provides the radiology
ACT Genomics, an integrated cancer molecular information company that transforms precision cancer care, has raised USD 12.5 million in Series B funding.
Hotung Group, and CDIB Capital Management, led the round with continued participation from existing investors, Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital in this round.
Based in Taipei, Taiwan, ACT Genomics is providing comprehensive genomic profiling assays and molecular information to physicians and biopharmaceutical customers. With full spectrum of clinical service, ACT Genomics helps to expand targeted therapy treatment options, predict response to immune-checkpoint inhibitors, and utilise ctDNA based assay to monitor
A survey carried out by RSM amongst private equity specialists has revealed that two thirds are planning to vote to remain in the EU when British voters take to the polling booths on 23 June, with only a fifth saying they would be voting to leave.
The survey, carried out among around 100 industry professionals within the private equity sector, found that three-quarters (74 per cent) of the respondents said they believed that leaving the EU could result in conditions for private equity deals declining for up to two years, with nearly a quarter (23 per cent) saying this could
New research from BNY Mellon finds that private equity, real estate and infrastructure managers anticipate strong growth in assets in the next five years. The research, Building for the future: How alternative investment managers are rising to the demographic challenge, was prepared in collaboration with Preqin, finds that global macro-economic, social and environmental shifts are fuelling a need for investments in real assets, property and infrastructure worldwide.
The report forecasts that appetite for these assets among retail and institutional investors will continue to grow. Sixty per cent of infrastructure managers, 44 per cent of real estate managers and 39 per
Navigating the increased regulatory requirements of AIFMD has been a costly and resource-intensive exercise for many investment managers over the past few years. Now that the dust has settled on AIFMD, fund managers need to decide on, and implement, the most efficient operating models that allow them to manage assets and raise new capital.
Last month, SEI hosted a panel session in London in conjunction with Duff & Phelps, EFA and leading alternative investment managers entitled “Practical AIFM Management Company Operating Models for Investment Managers”, to specifically address the ways in which managers might wish to establish new European fund
Humanyze, a specialist in people analytics technology, has secured USD4 million in Series A financing from Romulus Capital.
The announcement comes as Humanyze rolls out the first of its kind Wyze people analytics platform to its strong Fortune 500 customer base in the US and industry leaders in Japan with the goal of making large corporations more agile and accurate about their most valuable resource (people), and to make these same people more in control of their performance and improvement.
“Our customers – which include the largest multinationals and consulting firms – are investing heavily in technology and personnel to
Ogier is acting as British Virgin Islands legal counsel to Atlantic Alliance Partnership Corp on its recently announced recommended offer for TLA Worldwide plc.
TLA Worldwide plc (TLA) is a leading athlete representation, sports marketing and event management company which represents a number of prominent US and International sports stars, broadcasters and media personalities.
TLA also provides a range of services in respect of media consultancy, sports sponsorship and events. TLA is a public company incorporated in England with its shares are listed on the AIM market of the London Stock Exchange. Atlantic’s offer for TLA, which was announced under
venBio Partners has held the closing of the venBio Global Strategic Fund II, its second life sciences venture capital fund, for a total of approximately USD315 million, exceeding its target of USD250 million.
venBio's Strategic Fund II is anchored by major investments from three strategic limited partners – Amgen, Merck, and Baxalta – along with a group of financial Limited Partners.
"We believe our fund model is unique. With the return of Amgen and Baxalta, along with the addition of Merck, the commitment from our Strategic Limited Partners is now larger than ever," says Robert Adelman, MD, managing partner at
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
